Health Canada Grants Authorization for LEQEMBI (lecanemab) for the Treatment of Early Alzheimers Disease
In Canada, lecanemab is indicated for the treatment of adult patients with…
Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock
October 15, 2025 17:15 ET Â | Source: Annovis Bio Inc. MALVERN, Pa.,…
Alamar Biosciences Launches NULISAqpcr BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer’s Disease Research
New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next…
HKUST Scientists Reveal Critical Impacts of a Chinese Genetic Risk Factor in Alzheimer’s Disease
HONG KONG, Oct. 2, 2025 /PRNewswire/ -- A landmark study conducted by…
LEQEMBI (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimers Disease Approved in China
September 28, 2025 19:30 ET Â | Source: Biogen Inc. TOKYO and CAMBRIDGE,…
Where Empathy Meets Compassion: Championing Alzheimer’s Awareness
This World Alzheimer's Day, doctors, patients and their caregivers gathered for an…
NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimers Disease Program
The $2.5 Million in NIH STTR Phase 2 Grant allows NanoNewron to…
C2N Announces Major Global Expansion, Adds Six New International Partners
PrecivityAD2â„¢ blood test now available in over seven additional countries with primary…
FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: SNAP BENEFITS LINKED TO SLOWER COGNITIVE DECLINE, 10-YEAR STUDY FINDS
Key Takeaways Participating in the Supplemental Nutrition Assistance Program (SNAP) may help…
FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: ALZHEIMER’S ASSOCIATION RELEASES ITS FIRST CLINICAL PRACTICE GUIDELINE FOR BLOOD-BASED BIOMARKER TESTS
Key Takeaways At AAIC 2025, the Alzheimer's Association released the first in…